サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1788251

PARP阻害剤のバイオマーカーの世界市場

PARP Inhibitor Biomarkers

出版日
ページ情報
英文 278 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
PARP阻害剤のバイオマーカーの世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 278 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

PARP阻害剤のバイオマーカーの世界市場は2030年までに15億米ドルに達する

2024年に9億5,170万米ドルと推定されたPARP阻害剤のバイオマーカーの世界市場は、分析期間2024-2030年にCAGR 7.6%で成長し、2030年には15億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるPARP阻害剤バイオマーカーキットは、CAGR 8.8%を記録し、分析期間終了までに10億米ドルに達すると予測されます。PARP阻害剤バイオマーカーアッセイ分野の成長率は、分析期間中CAGR 5.3%と推定されます。

米国市場は2億5,930万米ドル、中国はCAGR12.1%で成長すると予測

米国のPARP阻害剤のバイオマーカー市場は、2024年には2億5,930万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを12.1%として、2030年までに3億1,740万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.7%と7.4%と予測されています。欧州では、ドイツがCAGR 5.1%で成長すると予測されています。

世界のPARP阻害剤のバイオマーカー市場- 主要動向と促進要因のまとめ

PARP阻害剤のバイオマーカー市場が勢いを増す理由とは？

PARP阻害剤のバイオマーカー市場は、がん領域におけるプレシジョン・メディシンの役割が高まるにつれて拡大しています。PARP（ポリADPリボースポリメラーゼ）阻害剤は、卵巣がん、乳がん、前立腺がん、膵がんなどの治療に用いられる標的治療薬の一種です。PARP阻害剤に反応する患者を特定するための予測バイオマーカーの必要性が、コンパニオン診断やゲノム検査の進歩を促しています。

さらに、次世代シークエンシング（NGS）やリキッドバイオプシー技術の利用可能性が高まることで、より正確なバイオマーカー同定が可能になり、治療選択と患者の転帰が改善されつつあります。PARP阻害剤の新たな応用を模索する臨床試験の拡大は、市場の需要をさらに促進しています。

ゲノム検査とコンパニオン診断は、PARP阻害剤のバイオマーカー同定をどのように変革しているか？

ゲノム検査のがん治療への統合は、PARP阻害剤バイオマーカー探索に革命をもたらしています。BRCA1/2変異検査、相同組換え欠損（HRD）アッセイ、ヘテロ接合体欠損（LOH）解析は、PARP阻害剤の有効性を予測するための標準的な検査になりつつあります。これらのバイオマーカーは腫瘍医が治療計画を調整するのに役立ち、治療成功率を向上させる。

コンパニオン診断も重要な役割を果たしており、規制機関はPARP阻害剤治療と同時にバイオマーカーに基づく検査を承認しています。AI主導のバイオインフォマティクス・ツールは、バイオマーカー同定をさらに洗練させ、精度と臨床的意思決定を高めています。

PARP阻害剤の適用拡大は市場成長を促進するか？

卵巣がんや乳がん以外にもPARP阻害剤の応用が拡大していることが、PARP阻害剤のバイオマーカーの市場を拡大しています。調査では、肺がん、膵臓がん、大腸がんでの使用が検討されており、患者選択の指針となるバイオマーカー検査の需要が高まっています。

さらに、PARP阻害剤と免疫チェックポイント阻害剤を含む併用療法の台頭が、バイオマーカー革新の原動力となっています。科学者たちは、腫瘍の微小環境と免疫反応を評価する予測検査を開発し、より個別化された治療戦略につなげています。

PARP阻害剤のバイオマーカー市場の成長の原動力は？

PARP阻害剤のバイオマーカー市場の成長は、プレシジョン・オンコロジーの採用の増加、ゲノム検査の進歩、PARP阻害剤の応用拡大によってもたらされます。コンパニオン診断やAIを活用したバイオマーカー同定に対する需要の高まりは、市場の成長をさらに加速させています。

さらに、バイオマーカー主導型治療に対する規制当局の承認、がん研究への投資の増加、NGSとリキッドバイオプシー技術の統合が技術革新を促進しています。個別化がん治療が進化し続けるにつれて、PARP阻害剤のバイオマーカーの需要は大幅に増加すると予想されます。

セグメント

製品タイプ（PARP阻害剤バイオマーカーキット、PARP阻害剤バイオマーカーアッセイ）;アプリケーション（乳がんアプリケーション、卵巣がんアプリケーション、その他のアプリケーション）

調査対象企業の例

  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Amoy Diagnostics Co., Ltd.
  • AstraZeneca
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE N.V.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Genway Biotech, Inc.
  • GlaxoSmithKline（GSK）
  • Illumina, Inc.
  • Invitae Corporation
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • Pfizer Inc.
  • QIAGEN
  • Siemens Healthcare GmbH
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32485

Global PARP Inhibitor Biomarkers Market to Reach US$1.5 Billion by 2030

The global market for PARP Inhibitor Biomarkers estimated at US$951.7 Million in the year 2024, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. PARP Inhibitor Biomarker Kits, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the PARP Inhibitor Biomarker Assays segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$259.3 Million While China is Forecast to Grow at 12.1% CAGR

The PARP Inhibitor Biomarkers market in the U.S. is estimated at US$259.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$317.4 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global PARP Inhibitor Biomarkers Market - Key Trends & Drivers Summarized

Why Is the PARP Inhibitor Biomarkers Market Gaining Momentum?

The PARP inhibitor biomarkers market is expanding as the role of precision medicine in oncology continues to grow. PARP (poly ADP-ribose polymerase) inhibitors are a class of targeted therapies used in the treatment of cancers such as ovarian, breast, prostate, and pancreatic cancer. The need for predictive biomarkers to identify patients who will respond to PARP inhibitors is driving advancements in companion diagnostics and genomic testing.

Additionally, the increasing availability of next-generation sequencing (NGS) and liquid biopsy technologies is enabling more precise biomarker identification, improving treatment selection and patient outcomes. The expansion of clinical trials exploring new applications of PARP inhibitors is further fueling market demand.

How Are Genomic Testing and Companion Diagnostics Transforming PARP Inhibitor Biomarker Identification?

The integration of genomic testing into cancer care is revolutionizing PARP inhibitor biomarker discovery. BRCA1/2 mutation testing, homologous recombination deficiency (HRD) assays, and loss-of-heterozygosity (LOH) analysis are becoming standard tests for predicting PARP inhibitor efficacy. These biomarkers help oncologists tailor treatment plans, improving therapeutic success rates.

Companion diagnostics are also playing a crucial role, with regulatory agencies approving biomarker-based tests alongside PARP inhibitor therapies. AI-driven bioinformatics tools are further refining biomarker identification, enhancing accuracy and clinical decision-making.

Is the Expansion of PARP Inhibitor Applications Driving Market Growth?

The growing application of PARP inhibitors beyond ovarian and breast cancer is expanding the market for PARP inhibitor biomarkers. Research is exploring their use in lung, pancreatic, and colorectal cancers, increasing the demand for biomarker testing to guide patient selection.

Additionally, the rise of combination therapies involving PARP inhibitors and immune checkpoint inhibitors is driving biomarker innovation. Scientists are developing predictive tests that assess tumor microenvironments and immune response, leading to more personalized treatment strategies.

What’s Driving the Growth of the PARP Inhibitor Biomarkers Market?

The growth in the PARP inhibitor biomarkers market is driven by the increasing adoption of precision oncology, advancements in genomic testing, and the expansion of PARP inhibitor applications. The rising demand for companion diagnostics and AI-powered biomarker identification is further accelerating market growth.

Additionally, regulatory approvals for biomarker-driven therapies, the growing investment in cancer research, and the integration of NGS and liquid biopsy technologies are fueling innovation. As personalized cancer treatment continues to evolve, the demand for PARP inhibitor biomarkers is expected to rise significantly.

SCOPE OF STUDY:

The report analyzes the PARP Inhibitor Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (PARP Inhibitor Biomarker Kits, PARP Inhibitor Biomarker Assays); Application (Breast Cancer Application, Ovarian Cancer Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Agilent Technologies, Inc.
  • Ambry Genetics
  • Amoy Diagnostics Co., Ltd.
  • AstraZeneca
  • Bio-Rad Laboratories, Inc.
  • CENTOGENE N.V.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Genway Biotech, Inc.
  • GlaxoSmithKline (GSK)
  • Illumina, Inc.
  • Invitae Corporation
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • Pfizer Inc.
  • QIAGEN
  • Siemens Healthcare GmbH
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • PARP Inhibitor Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Precision Oncology Throw Spotlight on Biomarker-Guided PARP Inhibitor Therapies
    • Growing Clinical Validation of BRCA and HRD Biomarkers Accelerates Diagnostic Adoption
    • FDA Approvals and Expanded Indications Propel Growth in Companion Diagnostics
    • Increasing Use of Genomic Testing in Ovarian, Breast, and Prostate Cancer Supports Market Expansion
    • Rising Investment in Targeted Cancer Therapies Strengthens Business Case for Biomarker Discovery
    • Integration of Next-Generation Sequencing Enhances Detection Accuracy and Clinical Utility
    • Reimbursement Expansion for Molecular Diagnostic Panels Drives Adoption in Oncology Workflows
    • Strategic Collaborations Between Pharma and Diagnostic Firms Accelerate Commercialization
    • Growing Role of Tumor Profiling in Therapy Selection Expands Demand for Companion Biomarkers
    • Emergence of Liquid Biopsy-Based Assays Opens Up Non-Invasive Testing Opportunities
    • Academic Research and Clinical Trials Fuel Development of Novel Predictive Biomarkers
    • Global Push for Personalized Cancer Care Supports Inclusion of PARP Biomarkers in Guidelines
    • Integration with AI and Data Analytics Tools Improves Biomarker Interpretation and Treatment Decisions
    • Pharmaceutical Pipeline Expansion of PARP Inhibitors Creates Parallel Demand for Diagnostic Ecosystem
    • Regulatory Harmonization in Biomarker Validation Enhances Global Market Accessibility
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World PARP Inhibitor Biomarkers Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for PARP Inhibitor Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for PARP Inhibitor Biomarker Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for PARP Inhibitor Biomarker Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for PARP Inhibitor Biomarker Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for PARP Inhibitor Biomarker Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for PARP Inhibitor Biomarker Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for PARP Inhibitor Biomarker Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Breast Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Breast Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ovarian Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ovarian Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Ovarian Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for PARP Inhibitor Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for PARP Inhibitor Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for PARP Inhibitor Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • PARP Inhibitor Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for PARP Inhibitor Biomarkers by Product Type - PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for PARP Inhibitor Biomarkers by Product Type - Percentage Breakdown of Value Sales for PARP Inhibitor Biomarker Kits and PARP Inhibitor Biomarker Assays for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for PARP Inhibitor Biomarkers by Application - Breast Cancer Application, Ovarian Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for PARP Inhibitor Biomarkers by Application - Percentage Breakdown of Value Sales for Breast Cancer Application, Ovarian Cancer Application and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION